Literature DB >> 86834

Severe hypertension after ingestion of an appetite suppressant (phenylpropanolamine) with indomethacin.

K Y Lee, L J Beilin, R Vandongen.   

Abstract

Severe systemic hypertension developed in a patient who took indomethacin shortly after ingesting an appetite suppressant ('Trimolets') containing phenylpropanolamine. The hypertension was attributed to a drug interaction whereby the inhibition of prostaglandin synthesis by indomethacin exacerbated the sympathomimetic effects of phenylpropanolamine. It is suggested that withdrawal of preparations containing phenylpropranolamine from general use should be considered in view of their potential for adverse reactions with other commonly used drugs and their doubtful therapeutic value.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 86834     DOI: 10.1016/s0140-6736(79)91791-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  8 in total

1.  Treatment of seasonal and perennial rhinitis.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-09-26

2.  The inhibition of tyramine oxidation and the tyramine hypertensive response ("cheese effect") may be independent phenomena.

Authors:  M Sandler; V Glover; A Ashford; A Esmail
Journal:  J Neural Transm       Date:  1980       Impact factor: 3.575

3.  Phenylpropanolamine and cerebral hemorrhage.

Authors:  J R McDowell; H J LeBlanc
Journal:  West J Med       Date:  1985-05

Review 4.  Fixed combination drug therapy.

Authors:  G M Shenfield
Journal:  Drugs       Date:  1982-06       Impact factor: 9.546

Review 5.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

Review 6.  Non-prescription sympathomimetic agents and hypertension.

Authors:  S S Chua; S I Benrimoj
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Sep-Oct

7.  Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect?

Authors:  N Mendis; C M Pare; M Sandler; V Glover; G M Stern
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

8.  Regulatory decisions in a globalised world: the domino effect of phenylpropanolamine withdrawal in Latin America.

Authors:  Albert Figueras; Joan-Ramon Laporte
Journal:  Drug Saf       Date:  2002       Impact factor: 5.228

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.